Fischer J., Ganellin C.R., Rotella D.P. (Eds.) Analogue-based Drug Discovery III

Wiley, 2013. — 390 p.Most drugs are analogue drugs. There are no general rules how a new drug can be discovered, nevertheless, there are some observations which help to find a new drug, and also an individual story of a drug discovery can initiate and help new discoveries. Volume III is a continuation of the successful book series with new examples of established and recently introduced drugs. The major part of the book is written by key inventors either as a case study or a study of an analogue class. With its wide range across a variety of therapeutic fields and chemical classes, this is of interest to virtually every researcher in drug discovery and pharmaceutical chemistry, and - together with the previous volumes - constitutes the first systematic approach to drug analogue development.List of Contributors
General Aspects
Pioneer and Analogue Drugs
Competition in the Pharmaceutical Drug Development
Metabolic Stability and Analogue-Based Drug Discovery
Use of Macrocycles in Drug Design Exemplified with Ulimorelin, a Potential Ghrelin Agonist for Gastrointestinal Motility Disorders
Drug Classes
The Discovery of Anticancer Drugs Targeting Epigenetic Enzymes
Thienopyridyl and Direct-Acting P2Y12 Receptor Antagonist Antiplatelet Drugs
Selective Estrogen Receptor Modulators
Discovery of Nonpeptide Vasopressin V2 Receptor Antagonists
The Development of Cysteinyl Leukotriene Receptor Antagonists
Case Studies
The Discovery of Dabigatran Etexilate
The Discovery of Citalopram and Its Refinement to Escitalopram
Tapentadol – From Morphine and Tramadol to the Discovery of Tapentadol
Novel Taxanes: Cabazitaxel Case Study
Discovery of Boceprevir and Narlaprevir: A Case Study for Role of Structure-Based Drug Design
A New-Generation Uric Acid Production Inhibitor: Febuxostat